However, in randomized controlled trials (RCTs), a notable decrease in the risk of PCa was observed with thiazolidinediones (OR: 0.55; p = 0.04) and GLP-1-RA (OR: 0.53; p = 0.006), while no significant correlation was found with SGLT2 inhibitors (p = 0.3) [62]. The gene discussed is GLP1R; the disease is posterior cortical atrophy.